SCHEMBL10144737

SCHEMBL10144737

CCOC(=O)c1ccc(-n2[nH]c(C)cc2=O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.69
HTT P42858 5/20 0.69
KMT2A Q03164 4/20 0.69
GAA P10253 4/20 0.69
SMN1; SMN2 Q16637 4/20 0.69
MEN1 O00255 3/20 0.69
LMNA P02545 3/20 0.69
ALDH1A1 P00352 9/20 0.67
KDM4E B2RXH2 4/20 0.67
TDP1 Q9NUW8 3/20 0.67
RECQL P46063 1/20 0.56
HPGD P15428 3/20 0.55
HSP90AA1 P07900 1/20 0.55
CACNA1B Q00975 1/20 0.55
APBA1 Q02410 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
IDO1 P14902 1/20 0.53
POLB P06746 3/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
CA12 O43570 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29094080 0.85 ALDH1A1 (0.70) MAPTHTTKMT2AGAASMN1; SMN2
SCHEMBL12297727 0.82 ALDH1A1 (0.65) MAPTHTTKMT2AGAASMN1; SMN2
SCHEMBL394287 0.80 ALDH1A1 (1.00) MAPTHTTKMT2AGAASMN1; SMN2
SCHEMBL9196875 0.80 ALDH1A1 (0.62) MAPTHTTKMT2AGAASMN1; SMN2
SCHEMBL11773403 0.79 MAPT (0.74) MAPTHTTKMT2AGAASMN1; SMN2
SCHEMBL29094078 0.79 MAPT (0.65) MAPTHTTKMT2AGAASMN1; SMN2
SCHEMBL5527198 0.77 ALDH1A1 (0.60) MAPTHTTKMT2AGAASMN1; SMN2
SCHEMBL27419624 0.76 CA1 (0.79) MAPTHTTKMT2ASMN1; SMN2MEN1
SCHEMBL11426196 0.75 KDM4E (0.71) MAPTHTTKMT2AGAASMN1; SMN2
SCHEMBL10755227 0.75 ALDH1A1 (0.57) MAPTHTTKMT2AGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120100609-A1 N-LINKED GLYCAN BIOSYNTHESIS MODULATORS BIOMARIN PHARMACEUTICAL INC. 2012-04-26 US disclosed
US-20100248365-A1 GANGLIOSIDE BIOSYNTHESIS MODULATORS ZACHARON PHARMACEUTICALS, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120100609-A1 N-LINKED GLYCAN BIOSYNTHESIS MODULATORS ENGASE, GALNT1, GALNT13 MAPT 2982/4885HTT 3785/4885KMT2A 1652/4885
US-20100248365-A1 GANGLIOSIDE BIOSYNTHESIS MODULATORS UGCG, MAGT1, STT3B MAPT 4120/4885HTT 4596/4885KMT2A 1738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.